Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026

BHVN vs DNLI: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

BHVN Captures Overall Composite Edge (42.1 HOLD vs 55.5 HOLD), While DNLI Leads 3–2 on Growth & Valuation Pillars

BHVN Overall Winner 6-Pillar Tally: BHVN 2 – 3 DNLI (1 Tie) Matrix Metrics: BHVN 3 – 4 DNLI

As of Nov 16, 2026, Biohaven Ltd. (BHVN) captures the overall head-to-head institutional edge over Denali Therapeutics Inc. (DNLI) on higher Unified Composite conviction (42.1/100 HOLD vs. 55.5/100 HOLD) after splitting the core matrix 3–4 (led by Profitability & Quality, Options & Positioning), while DNLI wins 3–2 across the 6-pillar growth and valuation breakdown. BHVN trades at $13.90 (N/M Forward P/E, 0.0% operating margin) versus DNLI at $18.33 (N/M Forward P/E, -2481.1% operating margin).

  • Composite vs. Pillar Nuance: While DNLI currently prints a higher short-term Unified Composite Score (55.5/100 HOLD vs. BHVN 42.1/100 HOLD), BHVN captures the overall institutional head-to-head verdict (3–4 matrix metrics and 2–3 across the 6 pillars) due to superior fundamental profitability (0.0% vs. -2481.1% operating margin) and revenue trajectory (+0.0% vs. -100.0% YoY).
  • Technical & Structure Timing Caution: BHVN is currently in a Weinstein Distribution regime near a flattening 50-day moving average (RSI 48.4); meanwhile DNLI is in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 40.6). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About BHVN vs DNLI
BHVN NYSE Head-to-Head Winner
Biohaven Ltd.
Pharmaceutical Preparations
$13.90
+0.62% 1D
Market Cap $2.1B
TTM Revenue N/A
Forward P/E N/M
Beta / 30D Vol 1.41β · 111% Vol
Unified Composite Score
42.1 / 100 HOLD
Tech 15.0 Fund 42.0 Flow 68.0 Mom 50.0
Weinstein Technical Phase Distribution · Trim / tighten stop
Price near a flattening SMA50 (slope -0.9%) with fading momentum, RSI 48
RSI-14: 48.4 · SMA20: $14.55 · SMA50: $13.48
DNLI NASDAQ
Denali Therapeutics Inc. Common Stock
Biological Products, (No Disgnostic Substances)
$18.33
-2.19% 1D
Market Cap $3.0B
TTM Revenue $21M
Forward P/E N/M
Beta / 30D Vol 1.36β · 48% Vol
Unified Composite Score
55.5 / 100 HOLD
Tech 44.0 Fund 55.0 Flow 66.0 Mom 50.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -9.3%), weak momentum, RSI 41
RSI-14: 40.6 · SMA20: $19.25 · SMA50: $19.70

6-Pillar Scorecard Institutional Category Breakdown (BHVN 2 – 3 DNLI)

Columns: Metric · BHVN · DNLI
1. Valuation Multiples DNLI
Forward P/E N/M N/M
Trailing P/E N/M N/M
PEG Ratio N/M N/M
EV / Revenue N/M 138.2x
2. Growth & Scale DNLI
Revenue Growth (YoY) +0.0% -100.0%
Earnings Growth (YoY) +0.0% +0.0%
TTM Revenue (USD) N/A $21M
Market Cap $2.1B $3.0B
3. Profitability & Quality BHVN
Gross Margin N/A N/A
Operating Margin 0.0% -2481.1%
Net Profit Margin 0.0% 0.0%
Return on Equity (ROE) -799.5% -33.9%
4. Balance Sheet & Cash Flow DNLI
Cash Generation (TTM) -$473M -$486M
Cash Flow Margin N/A N/A
Net Cash / Leverage $205M Net Debt $73M Net Cash
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning BHVN
Options Structure Phase CONSOLIDATION BREAKDOWN
Current IV / %ile 91.5% (18th %ile) 78.2% (27th %ile)
Put/Call OI Skew 0.31x (Call-Skewed) 6.21x (Put-Skewed)
OBV Trend / Tech Phase NEUTRAL · Distribution DISTRIBUTION · Markdown
6. R&D & Supply-Chain Moat Tie
OpEx & R&D Intensity N/A N/A
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Biotechnology Operator Biotechnology Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: BHVN (3) vs DNLI (4)
Institutional Metric BHVN DNLI Criterion Row Edge
Market Capitalization
Scale
$2.1B $3.0B Larger Scale DNLI
Trailing P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Forward P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Revenue Growth (YoY)
Growth
+0.0% -100.0% Higher Growth BHVN
Operating Margin (TTM)
Profitability
0.0% -2481.1% Higher Margin BHVN
Net Profit Margin
Profitability
0.0% 0.0% Higher Margin Tie
Return on Equity (ROE)
Capital Efficiency
-799.5% -33.9% Higher ROE DNLI
52-Week Range Position
Momentum
59% ($8–$18) 25% ($15–$27) Stronger Trend BHVN
Beta / 30D Volatility
Risk Regime
1.41β · 111% Vol 1.36β · 48% Vol Lower Realized Risk DNLI
Unified Institutional Score
Composite Signal
42.1 / 100 (HOLD) 55.5 / 100 (HOLD) Higher Composite DNLI
Trailing 12M Revenue (USD)
Operating Scale
N/A $21M FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
N/A N/A Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · N/M EV/Rev N/M PEG · 138.2x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
-$473M ($205M Net Debt) -$486M ($73M Net Cash) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon BHVN +24.9 pp
BHVN: +28.99% · DNLI: +4.09%
3M Horizon BHVN +27.07 pp
BHVN: +2.47% · DNLI: -24.6%
6M Horizon BHVN +64.16 pp
BHVN: +63.78% · DNLI: -0.38%
1Y Horizon BHVN +65.21 pp
BHVN: +72.09% · DNLI: +6.88%

Financial Trajectory Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant USD Revenue & Operating Margin (%)

Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on BHVN vs DNLI. Trailing 12-month operating profitability (BHVN 0.0% vs DNLI -2481.1%) and valuation multiples (BHVN N/M vs DNLI N/M Forward P/E) are benchmarked directly in Pillar 4 below.

BHVN ADR TTM Benchmark FX-Normalized USD
TTM RevenueN/A
Gross MarginN/A
Op. Margin0.0%
ROE / Fwd P/E-799.5% · N/M
DNLI ADR TTM Benchmark FX-Normalized USD
TTM Revenue$21M
Gross MarginN/A
Op. Margin-2481.1%
ROE / Fwd P/E-33.9% · N/M

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
BHVN CONSOLIDATION
91d in phase · OBV NEUTRAL
Current IV 91.5%
IV Percentile 18th %ile
Put/Call OI Skew 0.31x (Call-Skewed)
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow NEUTRAL
Exact BHVN Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
DNLI BREAKDOWN
91d in phase · OBV DISTRIBUTION
Current IV 78.2%
IV Percentile 27th %ile
Put/Call OI Skew 6.21x (Put-Skewed)
IV Regime Balanced (25th–60th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BEARISH
OBV Flow DISTRIBUTION
Exact DNLI Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
BHVN Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $2.1B market capitalization and 0.0% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published
DNLI Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $3.0B market capitalization and -2481.1% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published

Investor FAQ BHVN vs DNLI Key Questions & Quantitative Answers

As of Nov 16, 2026, Biohaven Ltd. (BHVN) captures the overall head-to-head institutional edge over Denali Therapeutics Inc. (DNLI) on higher Unified Composite conviction (42.1/100 HOLD vs. 55.5/100 HOLD) after splitting the core matrix 3–4 (led by Profitability & Quality, Options & Positioning), while DNLI wins 3–2 across the 6-pillar growth and valuation breakdown. BHVN trades at $13.90 (N/M Forward P/E, 0.0% operating margin) versus DNLI at $18.33 (N/M Forward P/E, -2481.1% operating margin). Composite vs. Pillar Nuance: While DNLI currently prints a higher short-term Unified Composite Score (55.5/100 HOLD vs. BHVN 42.1/100 HOLD), BHVN captures the overall institutional head-to-head verdict (3–4 matrix metrics and 2–3 across the 6 pillars) due to superior fundamental profitability (0.0% vs. -2481.1% operating margin) and revenue trajectory (+0.0% vs. -100.0% YoY). Technical & Structure Timing Caution: BHVN is currently in a Weinstein Distribution regime near a flattening 50-day moving average (RSI 48.4); meanwhile DNLI is in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 40.6). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

DNLI leads the Growth & Scale pillar: BHVN posts +0.0% YoY revenue growth and +0.0% YoY earnings growth on N/A TTM revenue (N/A gross margin, 0.0% operating margin), compared with DNLI at -100.0% YoY revenue growth and +0.0% YoY earnings growth on $21M TTM revenue (N/A gross margin, -2481.1% operating margin). On trailing 12-month operating scale, BHVN generates N/A in USD-normalized revenue versus $21M for DNLI. In operating R&D and SG&A reinvestment, BHVN deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for DNLI.

DNLI screens cheaper on headline valuation multiples. BHVN trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported FCF margin), whereas DNLI trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 138.2x EV/Revenue (unreported FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against BHVN (-799.5% ROE) versus DNLI (-33.9% ROE) capital efficiency.

In options market volatility and institutional positioning, BHVN carries 91.5% implied volatility (18th %ile, Compressed (<25th %ile)), a 0.31x (Call-Skewed) Put/Call open-interest ratio, NEUTRAL on-balance volume, and sits in a CONSOLIDATION options structure phase (1.41β · 111% Vol realized risk). By comparison, DNLI carries 78.2% implied volatility (27th %ile, Balanced (25th–60th %ile)), a 6.21x (Put-Skewed) Put/Call open-interest ratio, DISTRIBUTION on-balance volume, and sits in a BREAKDOWN options structure phase (1.36β · 48% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.